<DOC>
	<DOCNO>NCT01638858</DOCNO>
	<brief_summary>In prospective , open-label clinical study investigate behavior retinal function development diabetic macular disease ( DME ) influence Lucentis . Measurements multifocal electroretinogram ( ERG ) microperimetry use objective criterion information retinal function obtain .</brief_summary>
	<brief_title>Treatment Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab ( Lucentis )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1. diabetic macular edema center involvement least one eye 2. patient central retinal thickness 3. patient BCVA 7824 EDTRS letter 4. decrease vision due DME due cause , opinion investigator 5 . Type 1 type 2 diabetes mellitus diagnose 2 year prior screen 1. history evidence severe cardiac disease 2. clinical medical history uncontrolled hypertension diabetes 3. unstable angina , acute coronary syndrome , myocardial infarction revascularization 6 month 4. ventricular tachyarrhythmias require ongoing treatment 5. history evidence clinically significant peripheral vascular disease , intermittent claudication prior amputation 6. clinically significant impaired renal hepatic function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>